citalopram has been researched along with Breast Neoplasms in 13 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We aimed to evaluate and compare the efficacy of venlafaxine and citalopram on hot flashes in breast cancer women receiving tamoxifen." | 9.69 | Evaluation and Comparison of Citalopram and Venlafaxine for Management of Hot Flashes in Women with Breast Cancer. ( Esfandbod, M; Etesam, F; Taleghani, SY, 2023) |
| " Because the efficacy of escitalopram, a potent serotonin reuptake inhibitor, has not been well evaluated in cancer patients, we investigated its effects on depression and quality of life in outpatients with breast cancer." | 9.16 | Rapid improvement of depression and quality of life with escitalopram treatment in outpatients with breast cancer: a 12-week, open-label prospective trial. ( Bae, JN; Hahm, BJ; Kim, JH; Lee, BJ; Park, HY, 2012) |
| "Breast cancer patients with indications for an SSRI may be prescribed citalopram - and possibly other SSRI - without adversely affecting the outcome of adjuvant therapy with tamoxifen." | 7.76 | Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. ( Ahern, TP; Cronin-Fenton, D; Ewertz, M; Garne, JP; Hamilton-Dutoit, S; Lash, TL; Lunetta, KL; Pedersen, L; Rosenberg, CL; Silliman, RA; Sørensen, HT, 2010) |
| "Tamoxifen remains an important adjuvant therapy to reduce the rate of breast cancer recurrence among patients with oestrogen-receptor-positive tumours." | 7.74 | Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram. ( Ahern, TP; Cronin-Fenton, D; Ewertz, M; Garne, JP; Hamilton-Dutoit, S; Lash, TL; Lunetta, KL; Pedersen, L; Rosenberg, CL; Silliman, RA; Sørensen, HT, 2008) |
| "We aimed to evaluate and compare the efficacy of venlafaxine and citalopram on hot flashes in breast cancer women receiving tamoxifen." | 5.69 | Evaluation and Comparison of Citalopram and Venlafaxine for Management of Hot Flashes in Women with Breast Cancer. ( Esfandbod, M; Etesam, F; Taleghani, SY, 2023) |
| " Therefore we investigated whether there is a drug-drug interaction between tamoxifen and SRIs resulting in a prolonged QTc-interval." | 5.51 | The Risk of QTc-Interval Prolongation in Breast Cancer Patients Treated with Tamoxifen in Combination with Serotonin Reuptake Inhibitors. ( Berger, FA; Binkhorst, L; de Groot, NMS; Hussaarts, KGAM; Mathijssen, RHJ; Mathijssen-van Stein, D; Oomen-de Hoop, E; van Alphen, RJ; van Gelder, T; van Leeuwen, RWF, 2019) |
| " Because the efficacy of escitalopram, a potent serotonin reuptake inhibitor, has not been well evaluated in cancer patients, we investigated its effects on depression and quality of life in outpatients with breast cancer." | 5.16 | Rapid improvement of depression and quality of life with escitalopram treatment in outpatients with breast cancer: a 12-week, open-label prospective trial. ( Bae, JN; Hahm, BJ; Kim, JH; Lee, BJ; Park, HY, 2012) |
| "Breast cancer patients with indications for an SSRI may be prescribed citalopram - and possibly other SSRI - without adversely affecting the outcome of adjuvant therapy with tamoxifen." | 3.76 | Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. ( Ahern, TP; Cronin-Fenton, D; Ewertz, M; Garne, JP; Hamilton-Dutoit, S; Lash, TL; Lunetta, KL; Pedersen, L; Rosenberg, CL; Silliman, RA; Sørensen, HT, 2010) |
| "Tamoxifen remains an important adjuvant therapy to reduce the rate of breast cancer recurrence among patients with oestrogen-receptor-positive tumours." | 3.74 | Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram. ( Ahern, TP; Cronin-Fenton, D; Ewertz, M; Garne, JP; Hamilton-Dutoit, S; Lash, TL; Lunetta, KL; Pedersen, L; Rosenberg, CL; Silliman, RA; Sørensen, HT, 2008) |
| " Therefore we investigated whether there is a drug-drug interaction between tamoxifen and SRIs resulting in a prolonged QTc-interval." | 1.51 | The Risk of QTc-Interval Prolongation in Breast Cancer Patients Treated with Tamoxifen in Combination with Serotonin Reuptake Inhibitors. ( Berger, FA; Binkhorst, L; de Groot, NMS; Hussaarts, KGAM; Mathijssen, RHJ; Mathijssen-van Stein, D; Oomen-de Hoop, E; van Alphen, RJ; van Gelder, T; van Leeuwen, RWF, 2019) |
| "As a result, SSRIinduced akathisia is very frequently under-recognized." | 1.40 | A case of akathisia induced by escitalopram: case report & review of literature. ( Basu, B; De, S; Dutta, N; Gangopadhyay, T; Mandal, B; Mondal, S, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 10 (76.92) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Taleghani, SY | 1 |
| Etesam, F | 1 |
| Esfandbod, M | 1 |
| Hussaarts, KGAM | 1 |
| Berger, FA | 1 |
| Binkhorst, L | 1 |
| Oomen-de Hoop, E | 1 |
| van Leeuwen, RWF | 1 |
| van Alphen, RJ | 1 |
| Mathijssen-van Stein, D | 1 |
| de Groot, NMS | 1 |
| Mathijssen, RHJ | 1 |
| van Gelder, T | 1 |
| Basu, B | 1 |
| Gangopadhyay, T | 1 |
| Dutta, N | 1 |
| Mandal, B | 1 |
| De, S | 1 |
| Mondal, S | 1 |
| Biglia, N | 1 |
| Bounous, VE | 1 |
| Susini, T | 1 |
| Pecchio, S | 1 |
| Sgro, LG | 1 |
| Tuninetti, V | 1 |
| Torta, R | 1 |
| Lash, TL | 3 |
| Pedersen, L | 2 |
| Cronin-Fenton, D | 3 |
| Ahern, TP | 2 |
| Rosenberg, CL | 2 |
| Lunetta, KL | 2 |
| Silliman, RA | 2 |
| Hamilton-Dutoit, S | 2 |
| Garne, JP | 2 |
| Ewertz, M | 2 |
| Sørensen, HT | 3 |
| Shchepotin, IB | 1 |
| Zotov, AS | 1 |
| Dobzhenko, MN | 1 |
| Appiani, F | 1 |
| Carroll, BT | 1 |
| Muñoz, C | 1 |
| Trecco, J | 1 |
| Park, HY | 1 |
| Lee, BJ | 1 |
| Kim, JH | 1 |
| Bae, JN | 1 |
| Hahm, BJ | 1 |
| Buyko, E | 1 |
| Beisswanger, E | 1 |
| Hahn, U | 1 |
| Rodríguez, J | 1 |
| Castañeda, G | 1 |
| Muñoz, L | 1 |
| Granet, R | 1 |
| Sutter, S | 1 |
1 review available for citalopram and Breast Neoplasms
| Article | Year |
|---|---|
[Selective serotonin reuptake inhibitors and mammary pathologies].
Topics: Antidepressive Agents; Breast Neoplasms; Citalopram; Clinical Trials as Topic; Female; Fluoxetine; F | 2010 |
3 trials available for citalopram and Breast Neoplasms
| Article | Year |
|---|---|
Evaluation and Comparison of Citalopram and Venlafaxine for Management of Hot Flashes in Women with Breast Cancer.
Topics: Adult; Aged; Breast Neoplasms; Citalopram; Double-Blind Method; Female; Hot Flashes; Humans; Menopau | 2023 |
Duloxetine and escitalopram for hot flushes: efficacy and compliance in breast cancer survivors.
Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Antidepressive Agents; Antidepressive Agent | 2018 |
Rapid improvement of depression and quality of life with escitalopram treatment in outpatients with breast cancer: a 12-week, open-label prospective trial.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Breast Neoplasms; Citalopram; Depressive Disorder, M | 2012 |
9 other studies available for citalopram and Breast Neoplasms
| Article | Year |
|---|---|
The Risk of QTc-Interval Prolongation in Breast Cancer Patients Treated with Tamoxifen in Combination with Serotonin Reuptake Inhibitors.
Topics: Aged; Antidepressive Agents, Second-Generation; Antineoplastic Agents, Hormonal; Breast Neoplasms; C | 2019 |
A case of akathisia induced by escitalopram: case report & review of literature.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Second-Generation; Breast Neoplasms; Citalopram; | 2014 |
Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Citalopram; Dr | 2008 |
Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antineoplastic Agents, Hormonal; Breast Neopl | 2010 |
Selective serotonin reuptake inhibitors and adjuvant tamoxifen therapy: risk of breast cancer recurrence and mortality.
Topics: Alleles; Antineoplastic Agents, Hormonal; Biotransformation; Breast Neoplasms; Citalopram; Cytochrom | 2010 |
Tamoxifen-SSRIs interaction: clinical manifestations of inhibition and lack of inhibition of CYP2D6.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal; Citalopram; Cytochrome P-450 | 2011 |
The extraction of pharmacogenetic and pharmacogenomic relations--a case study using PharmGKB.
Topics: Aryl Hydrocarbon Hydroxylases; Breast Neoplasms; Citalopram; Computational Biology; Cytochrome P-450 | 2012 |
Rapid determination of letrozole, citalopram and their metabolites by high performance liquid chromatography-fluorescence detection in urine: Method validation and application to real samples.
Topics: Antidepressive Agents, Second-Generation; Antineoplastic Agents; Breast Neoplasms; Chromatography, H | 2013 |
Can chemotherapy induce reactions of recollection?
Topics: Antidepressive Agents; Antineoplastic Agents; Breast Neoplasms; Citalopram; Depressive Disorder; Fem | 2007 |